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Abstract
Background: The TMPRSS2-ERG gene fusion occurs in about half of prostate cancer (PCa) cases and results in
overexpression of the transcription factor ERG. Overexpression of ERG has many effects on cellular function.
However, how these changes enhance cell growth and promote tumor development is unclear.
Methods: To investigate the role of ERG, LNCaP and PC3 cells were transfected with ERG and gene expression
and metabolic profile were analyzed.
Results: Our data show that expression of ERG induces overexpression of many nicotinicacetylcholine receptors
(nAChRs). In addition, metabolic profiling by LC-MS/MS revealed elevated production of several neurotransmitters in cells
expressing ERG. Consistently, treatment of ERG-expressing cells with nicotine induced elevated calcium influx, GSK3β
(Ser9) phosphorylation and cell proliferation. Finally, we show that PCa patientswho are smokers have larger tumors if
their tumors are TMPRSS2-ERG gene fusion positive.
Conclusion: Collectively, our data suggest that ERG sensitizes prostate tumor cells to neurotransmitter receptor agonists
like nicotine.
Background
Transcription factor expression and function is com-
monly disrupted in cancer, leading to the gain or loss of
critical characteristics required for tumor development.
One such example, found in 50 % of prostate cancers,
involves the fusion between the ETS transcription fac-
tor ERG with the androgen-regulated gene TMPRSS2,
resulting in overexpression of ERG in the prostate epi-
thelium [1]. Overexpression of ERG drives a number of
oncogenic effects in prostate cells. For example, ERG
co-operates with the PI3K pathway to promote onco-
genesis [2, 3]. ERG also increases androgen receptor
(AR) binding in mouse prostate, and increases AR tran-
scriptional output in PTEN-deficient prostate cancer pa-
tients [4]. ERG-dependent chromatin modification has
also been found by many Chip-Seq studies that also
revealed that AR binding is significantly altered in
ERG-expressing cells [4–6]. ERG may regulate these
changes by altering expression of the histone deacety-
lase, HDAC1, as this is one of the most up-regulated
genes in ERG-positive prostate cancer. ERG also in-
duces expression of EZH2, a H3K27 methyl-transferase
critically involved in chromatin modification [7]. Add-
itionally, ERG has been found to enhance signaling through
the WNT pathway, an event that results in increased acti-
vation of β-catenin [8–10]. While these roles suggest an im-
portant role for ERG in tumorigenesis, in vivo mouse
models have found that ERG overexpression alone is insuf-
ficient to induce cancer [3, 4]. However, patients with ERG-
positive high-grade prostatic intraepithelial neoplasia
(HGPIN) are much more likely to progress to prostate can-
cer [11]. Therefore, the question still remains, if the
TMPRSS2:ERG fusion alone is not sufficient to cause
cancer, what changes does it induce in prostate epithe-
lial cells to predispose them to become cancerous.
Here we investigated the role of ERG in prostate cancer
and found that overexpression of ERG resulted in
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expression of a number of neurotransmitter receptors.
We found that these receptors were functional and
treatment of ERG-positive cells with the acetylcholine
receptor agonist, nicotine, increased cell growth, calcium
signaling and GSK-3β (Ser9) phosphorylation. As a result of
this, we measured the polar metabolic profile of ERG-
positive cells and found several elevated neurotransmitters.
Finally, we found that if patients with TMPRSS2:ERG
fusion positive prostate cancer were smokers, they had
significantly higher number of biopsy cores positive for
cancer, and each core contained a larger proportion of
tumor tissue, compared to TMPRSS2:ERG negative
smokers, suggesting an increased tumor volume in
these patients. Together, these data suggest a novel
mechanism by which ERG may contribute to prostate
tumorigenesis.
Materials and Methods
Patient data & Ethics Statement
Data analyzed in this work was extracted from the
BIDMC Early Detection Research Network (EDRN),
which enrolled men at 6 clinical practice sites at Harvard,
Michigan, and Cornell universities who had undergone
their first prostate biopsy were identified. Demographic and
pre-biopsy clinical data, including PSA history, digital rectal
exam (DRE) results, smoking history, prostate volume and
all biopsy procedure details were ascertained on case report
forms. Prostate biopsy results were reviewed with reports
confirmed by institutional pathologists. Pathology reports
included confirmed histology, number of cores and
percent of each core involved with carcinoma, and pri-
mary and secondary Gleason patterns [12]. Among pa-
tients with newly diagnosed (untreated) prostate cancer,
TMPRSS2:ERG status was determined using a PCR-based
urine TMPRSS2:ERG fusion assay (performed by Gen-
Probe, CA) as previously described [13].
All participants had provided written informed con-
sent and all prostate biopsies had been offered according
to National Comprehensive Cancer Network (NCCN)
guidelines [14].
All research carried out on humans was in compliance
with the Helsinki Declaration and approved by the
Dana-Farber/Harvard cancer Center Internal Review
Board protocol #DF/HCC 05-209.
Transfection of cells
ERG-RFP or RFP expression was induced in the PC3
and LNCaP cells using a lentiviral transduction system
provided by Dr. Owen Witte (UCLA, Los Angeles, CA)
as described previously [15].
Microarray and PCR gene expression analysis
Gene expression was assessed using Affymetrix’s (Santa
Clara, CA) GeneChip Human Genome U133 2.0 arrays.
Arrays were scanned with the GeneChip Scanner 3000 and
GeneChip Operating Software acquired raw fluores-
cence signal. Scanned array images were analyzed by
dChip [16] and CEL file data were normalized using
RMAexpress (http://rmaexpress.bmbolstad.com) [17]
and annotated using Multiexperiment Viewer software
(http://www.tm4.org/mev.html). The data generated have
been deposited in NCBI's Gene Expression Omnibus and
are accessible through GEO Series accession number
GSE55944 (http://www.ncbi.nlm.nih.gov/gds/?term=GSE55
944). Primers for select gene subsets were designed using
the Primer3 platform (http://bioinfo.ut.ee/primer3/)
and analyzed using a StepOnePlus real-time PCR ma-
chine from Applied Biosystems (Life Technologies,
Grand Island, NY).
Pathway and Upstream Regulator Analysis
Pathway analysis of the differentially expressed RT-
PCR-validated genes (Fig. 2) in ERG- and ERG+ LNCap
cells was performed using the commercial systems
biology oriented package, Ingenuity Pathways Analysis
(www.ingenuity.com). The Score (-log p-value) is calcu-
lated using Fisher's Exact Test and indicates the likeli-
hood a gene will be found in a network due to random
chance. Ingenuity's Upstream Regulator Analysis tool
was used to identify the cascade of upstream transcrip-
tional regulators that can explain the observed gene
expression changes.
Metabolomics
Metabolite content measurement in LNCap-ERG+ and
LNCap-ERG- cells and data analysis was performed as
described previously [18–20]. Briefly, 106 cells exponen-
tially growing in media were harvested in 3 mL of cold
80 % v/v HPLC grade methanol. Fresh medium was
added 24 and 2 h prior to the extraction. Samples were
re-suspended in 20 μL HPLC-grade water for mass spec-
trometry analysis. 10 μL were injected and analyzed
using a 5500 QTRAP triple quadrupole mass spectrom-
eter (AB/SCIEX) coupled to a Prominence UFLC HPLC
system (Shimadzu) via selected reaction monitoring
(SRM) of a total of 256unique endogenous polar metab-
olites for steady-state analyses. Peak areas from the total
ion current for each metabolite SRM transition were in-
tegrated using MultiQuant v2.0 software (AB/SCIEX).
Measurements were performed in triplicate and only me-
tabolites that were determined in all 6 samples were
retained, normalized and analyzed using MetaboAnalyst2.0
software (http://www.metaboanalyst.ca/MetaboAnalyst/).
Ca2+ flux
To investigate calcium signaling in prostate cancer cell
lines, cells were stained with 1 μM of Fluo-4 AM for
15 min at 37 °C in Hanks Buffered Salt Solution. Cells
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were then treated with 10 μM solution of nicotine and
intracellular Ca2+ concentration over time analyzed by
flow cytometry (BeckmanCoulter, Galios).
Pathscan and Western blot analysis of phospho-proteins
Nicotine- or buffer-treated cells were lysed on ice at the
various time points with Cell Signaling Technologies cell
lysis buffer. Protein concentration was determined using
the Thermo Scientific BCA protein assay kit. Analysis of
phospho-proteins was performed using Cell Signaling
PathScan Akt signaling array (Cat: 9700) as described by
the manufacturer’s instructions. Confirmation of PathScan
results was performed by western blot. Briefly, protein was
separated usingLife Technologies NovexSDS-Page sys-
tem. Antibodies from Cell SignallingT echnolgy against
phospho-GSK3a/b (Ser21/9) (clone 37 F11), β-actin
(clone 13E5) and phospho-AKT (Ser129) (clone D4P7F)
were used to detect relevant proteins under conditions
suggested by the manufacturer.
Statistics
Statistical analysis was performed using the Student’s
T-test. P values of less than 0.05 were considered
significant.
Results
ERG overexpression alone induces expression of
neurotransmitter receptor genes in LNCaP cells
To investigate how expression of ERG alters the function
of prostate cancer cells, LNCaP cells were transduced
with ERG or a control lentivirus, and transcriptional and
metabolic profiling was undertaken. Transcriptional pro-
filing found that amongst the genes up-regulated by
ERG were a number of neurotransmitter receptors. To
further investigate how expression of neurotransmitter
receptors was changed by ERG, we profiled all known
acetylcholine, and glutamate receptors by qRT-PCR (See
Additional file 1). The nicotinic acetylcholine receptors,
CHRNB1, CHRNB2, CHRNB4 and CHRNA3 all in-
creased from an undetectable level in control LNCaP to
high levels of expression in LNCaP-ERG cells (Fig. 1a).
Similarly, the adrenergic receptors, ADRA2A and
ADRA1D, and the glutamate receptors, GRIA2 and
GRIN1 were all highly up-regulated in the ERG-
positive cells (See Additional file 1: Table S1 for full
neurotransmitter expression data). Similar increase in
expression of these genes was observed in ERG-positive
PC3 cells and additionally, VCaP cells express far greater
levels of all these neurotransmitter receptors than either
wild-type LNCaP or PC3, further supporting the hypothesis
Fig. 1 Gene expression of select neurotransmitter receptors in ERG-expressing and control prostate cancer cell lines. a PCR analysis of LNCaP cells
expressing ERG or vector control. Data is representative of 2 experiments. *P < .05 for ERG vs. Vector control. Sets of differentially expressed
neurotransmitter receptor genes (derived from Additional file 1: Table S1) between ERG+ and control LNCap cells as assessed by qRT-PCR were
analyzed through the IPA package. Top dysregulated pathways in ERG+ cells (b) and predicted alterations in upstream regulators (c) are shown
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that ERG induces expression of these genes. To predict the
potential implications of CHRN receptor overexpression in
LNCap cells, we used the qRT-PCR data mentioned above
to perform an in silico analysis using the Ingenuity Pathway
Analysis tool. Our analysis revealed significant dysregula-
tions in many known neuronal signaling pathways. These
include Calcium Signaling, Glutamate Receptor signaling,
Neuropathic Pain Signaling In Dorsal Horn Neurons,
Synaptic Long Term Potentiation, G-Protein Coupled Re-
ceptor Signaling, and Dopamine-DARPP32 Feedback in
cAMP Signaling (Fig. 1b). Likewise, upstream regulator
analysis of the same PCR data identified patterns that
mimic the action of nicotine, dopamine, kainic acid,
flupenthixol, ethanol, beta-estradiol and Brain-derived
neurotrophic factor (Fig. 1c). In addition to these neuro-
transmitter receptors, several other genes associated with
nervous system were upregulated including CD24, the
neural stem cell marker was one of the most highly up reg-
ulated genes, as was the neural transcription factor TOX3
(Fig. 2). These genes were also increased in PC3 cells trans-
fected with ERG, as well as being highly expressed in VCaP,
a cell line that naturally expresses the TMPRSS2:ERG
fusion (Fig. 2).
ERG expression significantly alters the metabolic profile
in LNCap cells
To further investigate changes in the prostate cancer cells
after ERG induction, we analyzed the metabolic profile of
the cells using high-throughput tandem mass-spectrometry
(LC-MS/MS) [18]. 256 metabolites were targeted using this
method and 52 of these were significantly regulated in the
ERG expressing cells (Fig. 2c). Additionally, ERG-positive
LNCaP cells clustered significantly compared to controls
(Fig. 2b). Energy production and cellular proliferation path-
ways were enriched in the ERG-positive cells including
protein biosynthesis, gluconeogenesis and purine and
pyrimidine metabolism (Fig. 3d). Most importantly, metab-
olites belonging to the excitatory neural signaling pathway
were increased. In particular, ERG-positive LNCaP cells
had a significant increase in the neuro-transmitting mole-
cules, quinolinate, choline and glutamate (Fig. 3e). Add-
itionally, two other members of the acetylcholine synthesis
pathway, CDP-choline and glycerophosphocholine, were
significantly increased. Together, these data suggest
that ERG induces an increase in expression of neuro-
transmitter receptors and production of neuro-
transmitting molecules.
Fig. 2 Gene expression in ERG expressing prostate cancer cell lines.qRT-PCR analysis of LNCaP or PC3 cells expressing ERG or vector control. VCaP
expression of the same genes analysed compared to WT LNCaP or PC3 cells. Data is representative of 2 experiments. *P < .05 for ERG vs. Vector
and Vcap vs. LNCap and PC3
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Nicotine enhances growth of ERG-positive prostate cancer
cells and induces Ca2+ influx and phosphorylation of
GSK3β
Given the over-expression of numerous acetylcholine re-
ceptors, we hypothesized that prostate cancer cells
would be more responsive to acetylcholine receptor ago-
nists. We investigated the role of nicotine in enhancing
the growth of ERG-positive LNCaP cells. ERG-positive
LNCaP cells were treated with 10 nM of nicotine or
vehicle control, and the number of cells was counted at
24-h intervals using cell imaging cytometry. Growth of
the LNCaP-ERG cells treated with nicotine was signifi-
cantly faster than controls with an average doubling time
of 59 h compared to 72 h for controls. In contrast, ERG
negative cells had no significant change in growth when
exposed to nicotine (Fig. 4a). Given these change in
growth kinetics of ERG expressing cells in response to
nicotine, we investigated downstream signaling events of
nicotine exposure. Nicotine treatment induced a signifi-
cant increase in intracellular Ca2+ after 30 s in ERG ex-
pressing cells compared to normal LNCaPs (Fig. 4b). To
further investigate signaling events, protein isolated from
ERG-positive cells treated with nicotine, glutamate or
epinephrine was analyzed with a multiplex phospho-
signaling array. Of the 18 different proteins measured, only
phospho-GSK3βwas increased at all time points following
nicotine exposure (Fig. 4c, Additional file 1: Data 2 for all
phosphorylation data). Additionally, other neurotransmitter
receptor agonists Epinephrine and Glutamate increased
GSK3β phosphorylation. Phosphorylation of GSK3βwas
further investigated by western blot and a similar re-
sponse to all neurotransmitters found (Fig. 5d). These
findings indicate that over-expression of ERG confers the
ability on prostate cancer cells to respond to acetylcholine
receptor agonist through normal GPCR signaling pathways.
TMPRSS2:ERG+ prostate cancer patients that smoke have
a larger proportion of biopsy core involvement
Given our findings indicating that ERG-positive prostate
tumor cells exhibited expression of neurotransmitter re-
ceptors and that nicotine enhanced tumor cell growth
in vitro, we hypothesized that growth of ERG-positive
prostate cancer would be enhanced in patients that
smoked. We used data collected from a cohort of pa-
tients enrolled through the Early Detection Research
Network (EDRN) to correlate biopsy core involvement
to ERG and smoking status. Among patients with newly
diagnosed (untreated) prostate cancer in this cohort,
62 of these patients had their TMPRSS2:ERG status
determined using a urine TMPRSS2:ERG fusion assay
Fig. 3 Metabolite and Neurotransmitter production is elevated in LnCap and PC3 cells transfected with ERG. Among the metabolites (see
Methods Section) measured by LC-MS/MS, 52 were found to be significantly regulated in ERG+ LNCap as compared to ERG- LNCap (P < 0.05). Fold
change in production is shown in (a) and the t test in (b). Principal component analysis (PCA) provided evidence for clearly distinct metabolic phenotypes
comparing ERG+ LNCap and ERG- LNCap cells (c). The 52 metabolites include the neurotransmitters quinolinate, glycerophosphocholine, CDP-choline,
choline, and glutamate (d). Enrichment analysis identified many metabolic pathways in which the 52 differentially produced metabolites play a role (e)
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(See Additional file 1: Data #1 for all patient data). Of these
62 patients tested, 24 reported being regular smokers and
39 were positive for ERG (Fig. 5a). Interestingly, smokers
whose tumors had the TMPRSS2:ERG fusion had a signifi-
cantly higher number of both biopsy core involvement and
total core involvement, compared to patients whose tumors
are fusion negative (Fig. 5b and c). Similarly, given a patient
was positive for ERG, if they also smoked they had a near
significant (0 = 0.055) but no difference in number of cores
involved. In contrast, non-smokers had no significant differ-
ence in either of these measurements between ERG- and
ERG+ cancers. No significant difference in Gleason score or
T staging was observed between the ERG groups. These
data show in vivo evidence supporting genomic data that
suggested that ERG induced expression of neurotransmitter
receptors in prostate cancer cells, and a specific mechanism
by which ERG may contribute to tumor development.
Discussion
Expression of ERG is an early event in prostate cancer
tumorigenesis, but alone is insufficient to induce cancer
(3, 4). Here we investigated how ERG changed the func-
tion of prostate cancer cells by transducing LNCaP and
PC3 cells with ERG, and measuring changes in gene ex-
pression and metabolic profiles. Amongst the set of genes
most significantly changed, we found that expression of
ERG in LNCaP and PC3 cells caused up-regulation of
acetylcholine and adrenergic receptors (Fig. 1). Addition-
ally, metabolic profiling of these cell lines revealed an
increase in the concentration of excitatory neural signaling
Fig. 4 Treatment of LnCaP-ERG cells with nicotine enhances cell growth rate, calcium flux and phosphorylation of GSK-3β. a LNCaP cells transfected
with ERG or a control Vector were treated with nicotine and growth analysed by cell imaging cytometry. b Calcium Flux in cells treated with nicotine.
LNCaP cells were stained with Fluo-4 AM. Cells were then treated with nicotine and Calcium determined by flow cytometry. c Phospho-protein
analysis of nicotine treated cells. Protein was extracted from LNCaP-ERG or LNCaP vector cells treated with nicotine, epinephrine or glutamate and analyzed
by Pathscan (c) and Western Blot (d)
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molecules, choline, glutamate and quinolinate (Fig. 3). To
test the functionality of the neuro-transmitter receptors,
we treated cells with the acetylcholine receptor agonist,
nicotine. Signaling through these receptors induced an in-
crease in Ca2+ release, phosphorylation of GSK3β (Ser9)
and cell proliferation (Fig. 4). GSK3β phosphorylation at
Ser9 is a downstream event of many signal pathways in-
cluding WNT, AKT, and Ca2+ signaling [21]. GSK3β has
many effects that could contribute to tumor development.
This includes its central function as a regulator of glucose
metabolism and cell proliferation [21] and we found that
metabolites within both gluconeogenesis and the citric
acid cycle were two of the most enriched pathways of
ERG expressing cells (Fig. 4). Additionally, metabolites in-
volved in protein biosynthesis, purine metabolism, and
pyrimidine metabolism were all increased in ERG express-
ing cells, suggesting a higher metabolic rate in these cells
(Fig. 3). ERG has previously been reported to control
phosphorylation of GSK3β (Ser9) by regulating the WNT
pathway [8]. However, our data suggests a possible novel
mechanism by which ERG regulates GSK-3β; up-regulation
of neuro-transmitter receptors leading to an inappropriate
response to local neurotransmitters. In addition to these
general roles, GSK3βhas been suggested as a contributing
factor to prostate cancer cells gaining androgen independ-
ence [22]. Together, these findings suggest that ERG may
contribute to tumorigenesis through upregulating neuro-
transmitter receptors and increasing GSK3β phosphoryl-
ation and further downstream signaling events.
Given our findings of the increased growth response
to nicotine in vitro, we investigated whether ERG had a
similar effect on increasing susceptibility to nicotine in
PCa patients. We found that patients who smoked and
had TMRPSS2:ERG positive prostate cancer had a sig-
nificantly higher number of biopsy cores positive for
cancer, and these cores had a higher proportion of can-
cer involvement (Fig. 5). We acknowledge that the size
of this dataset is very small, and the lack of data regard-
ing the quantity and duration of the patients smoking
habits, or other unknown confounding variables, make
any certain claims about smoking leading to worse out-
comes for prostate cancer patients who are ERG positive
premature. However, this effect has been reported in
many other cancers, in particular in lung cancer where
nicotinic receptors regulate proliferation and inhibit
apoptosis [23, 24]. More recently, similar effects have been
described in bladder, breast and colon cancer [25, 26].
Based on the findings of other cancers and our in vitro
data, we believe that this patient data carries more weight
than an epidemiological study of this size usually would,
and suggests that larger epidemiological studies should in-
vestigate the link between ERG-positive prostate cancer,
smoking and prostate cancer disease outcome.
Conclusions
In summary, our data indicates that enhanced neuro-
transmitter receptor expression in ERG-expressing cells
translates into elevated responsiveness to exogenously
derived molecules like nicotine, or endogenous mole-
cules, glutamate and epinephrine. Also, in silico analysis
of the receptor expression data suggests that a similar
responsiveness might also develop towards other en-
dogenous molecules known to act on neurons, including
dopamine, kainic acid, flupenthixol, ethanol, β-estradiol
and Brain-derived neurotrophic factor. It is therefore
Fig. 5 Prostate cancer patients positive for ERG have larger tumors if
they are also smokers. a Venn Diagram showing smoking history
and urine PCR-determined TMPRSS2:ERG gene fusion status of
prostate cancer patients from the prostate cancer EDRN cohort.
b, c Histopathological analysis of TMPRSS2:ERG+ tumors from smokers
showed a higher number of biopsy cores involved and a higher
proportion of core involvement, compared to TMPRSS2:ERG- tumors
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possible that these molecules might negatively affect
ERG+PCa if they are present in the tumor microenviron-
ment. Together these data indicate that ERG has effects
on cell metabolism and proliferation by increasing cell
responsiveness to exogenous neurotransmitter receptor
agonists such as nicotine, and possibly to endogenous
neurotransmitters.
Additional file
Additional file 1: ERG-dependent neurotransmitter receptor
expression, pathscan data, and patient tumor pathology scoring.
(XLSX 100 kb)
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Novelty and impact
The TMPRSS2-ERG gene fusion occurs in about half of prostate cancer (PCa)
cases and results in overexpression of the transcription factor ERG. Here we
show that overexpression of ERG in prostate tumor cells increased expression
of acetylcholine receptors and enhanced responsiveness to receptor agonists
such as nicotine. This work offers a novel mechanism by which ERG contributes
to tumorigenesis.
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